WuXi Biologics Company Description

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.

It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.

It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities.

It has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.

The company was incorporated in 2014 and is headquartered in Wuxi, China.

WuXi Biologics (Cayman) Inc.

Country	Cayman Islands
Founded	2014
Industry	Commercial Physical and Biological Research
Employees	12,575
CEO	Zhisheng Chen

Contact Details

Address: No. 108, Meiliang Road Wuxi, 214092 China
Website	wuxibiologics.com

Stock Details

Ticker Symbol	WUXI06
Exchange	Stock Exchange of Thailand
Fiscal Year	January - December
Reporting Currency	CNY
SIC Code	8731

Key Executives

Name	Position
Zhisheng Chen	Chief Executive Officer
Ming Tu	Chief Financial Officer
Lihua Yu	Chief Operating Officer
Lina Fan	Head of Investor Relations